Novo Nordisk NVO
NYSE · Pharmaceutical Preparations$39.43−3.12%Nov 18 close · Databento
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via DatabentoRevenuekr 309.1B +6.4%
True FCF (ex-SBC)kr 59.0B −20.1%
Rule of 4025.5%
ROIC33.8%
FCF Margin19.1%
EPS, dilutedkr 23.03 +1.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio51%
FCF / sh—
EPS (diluted)kr 23.03
Compounder & Returns
Rule of 4025.5%
ROIC33.8%
Cash ROIC (CROIC)19.8%
GP / Assets46.1%
ROE52.8%
ROA18.9%
Gross Margin81.0%
Oper. Margin41.3%
Net Margin33.1%
FCF Margin19.1%
True FCF Margin19.1%
Quality & Dilution
Cash Conversion58%
Accrual Ratio−3.1%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate94%
Sales Growth Y/Y+6.4%
Sales 3Y CAGR+20.4%
EPS Growth Y/Y+1.8%
FCF Growth Y/Y−20.1%
FCF 3Y CAGR−4.0%
Share Change Y/Y—
Balance Sheet & Scale
Revenue (FY)kr 309.1B
Gross Profit (FY)kr 250.3B
Oper. Income (FY)kr 127.7B
GAAP Net Incomekr 102.4B
True FCF (ex-SBC)kr 59.0B
Cash & Equivkr 26.5B
Total Debtkr 131.0B
Net Cash (Debt)kr -104.5B
Net Cash % MCap—
Debt / FCF (yrs)2.2y
Current Ratio0.80
Price & Technicals (EOD)
Perf Week−4.04%
Perf Month+0.20%
Perf Quarter−14.54%
Perf Half Y−12.51%
Perf YTD−11.17%
SMA 20 Dist−1.95%$40.22
SMA 50 Dist−0.92%$39.80
SMA 100 Dist−9.92%$43.77
Window High−23.60%$51.61
Window Low+5.65%$37.32
RSI (14) · Vol45.235%v
Income Distribution & Cash Flow ConversionHow every dollar of NVO revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Where Every kr 100 of Revenue Goes (FY2025)
Cost of Revenue (COGS)kr 58.8B (kr 19.0 / kr 100)
R&D Reinvestmentkr 52.0B (kr 16.8 / kr 100)
SG&A & Other OpExkr 70.6B (kr 22.8 / kr 100)
Tax & Non-Operatingkr 25.2B (kr 8.2 / kr 100)
Net Profit Keptkr 102.4B (kr 33.1 / kr 100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2025)
GAAP Net Incomekr 102.4B (33.1% margin)
Operating Cash Flow (OCF)kr 119.1B(38.5% of rev)
Less: Capital Expenditures−kr 60.1B(19.5% of rev)
Standard Free Cash Flow (FCF)kr 59.0B(19.1% margin)
Less: Stock-Based Comp (SBC)—
True FCF (Owner Cash ex-SBC)kr 59.0B(19.1% of rev)
Revenue by fiscal year
Operating leverage — margins
GrossOperatingNet
| Line Item (DKK) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY Δ | 4Y CAGR | Trend |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | kr 140.8B | kr 177.0B | kr 232.3B | kr 290.4B | kr 309.1B | +6.4% | +21.7% | |
| Cost of Revenue (COGS) | kr 23.7B | kr 28.4B | kr 35.8B | kr 44.5B | kr 58.8B | +32.0% | +25.6% | |
| Gross Profit | kr 117.1B | kr 148.5B | kr 196.5B | kr 245.9B | kr 250.3B | +1.8% | +20.9% | |
| Research & Development (R&D) | kr 17.8B | kr 24.0B | kr 32.4B | kr 48.1B | kr 52.0B | +8.3% | +30.8% | |
| Selling, General & Admin (SG&A) | kr 4.0B | kr 4.5B | kr 4.9B | kr 5.3B | kr 6.0B | +13.1% | +10.2% | |
| Total Operating Expenses | kr 58.5B | kr 73.7B | kr 93.9B | kr 117.5B | kr 122.6B | +4.3% | +20.3% | |
| Operating Income (EBIT) | kr 58.6B | kr 74.8B | kr 102.6B | kr 128.3B | kr 127.7B | −0.5% | +21.5% | |
| Interest Expense | kr 2.5B | kr 6.0B | kr 845.0M | kr 7.3B | kr 6.8B | −7.7% | +29.0% | |
| Income Tax Expense | kr 11.3B | kr 13.5B | kr 21.0B | kr 26.2B | kr 28.1B | +7.3% | +25.5% | |
| GAAP Net Income | kr 47.8B | kr 55.5B | kr 83.7B | kr 101.0B | kr 102.4B | +1.4% | +21.0% | |
| Diluted EPS | kr 10.37 | kr 12.22 | kr 18.62 | kr 22.63 | kr 23.03 | +1.8% | +22.1% | |
| Balance Sheet | ||||||||
| Cash & Equivalents | kr 10.7B | kr 12.7B | kr 14.4B | kr 15.7B | kr 26.5B | +69.0% | +25.4% | |
| Inventory | kr 19.6B | kr 24.4B | kr 31.8B | kr 40.8B | kr 49.6B | +21.5% | +26.1% | |
| Total Current Assets | kr 85.6B | kr 108.2B | kr 139.6B | kr 161.8B | kr 172.5B | +6.6% | +19.1% | |
| Total Assets | kr 194.5B | kr 241.3B | kr 314.5B | kr 465.6B | kr 542.9B | +16.6% | +29.3% | |
| Total Current Liabilities | kr 99.5B | kr 120.9B | kr 169.7B | kr 217.6B | kr 215.7B | −0.9% | +21.3% | |
| Total Debt (Short + Long Term) | kr 26.6B | kr 25.8B | kr 27.0B | kr 102.8B | kr 131.0B | +27.4% | +48.9% | |
| Total Liabilities | kr 123.8B | kr 157.8B | kr 207.9B | kr 322.1B | kr 348.9B | +8.3% | +29.6% | |
| Stockholders' Equity | kr 70.7B | kr 83.5B | kr 106.6B | kr 143.5B | kr 194.0B | +35.2% | +28.7% | |
| Net Cash / (Net Debt) | kr -15.9B | kr -13.1B | kr -12.6B | kr -87.1B | kr -104.5B | −19.9% | — | |
| Invested Capital | kr 86.7B | kr 96.6B | kr 119.2B | kr 230.6B | kr 298.5B | +29.5% | +36.2% | |
| Cash Flow & Capital Allocation | ||||||||
| Operating Cash Flow (OCF) | kr 55.0B | kr 78.9B | kr 108.9B | kr 121.0B | kr 119.1B | −1.5% | +21.3% | |
| Depreciation & Amortization (D&A) | — | kr 6.6B | kr 7.3B | kr 8.5B | kr 14.7B | +71.6% | +30.8% | |
| Capital Expenditures (CapEx) | kr 6.3B | kr 12.1B | kr 25.8B | kr 47.2B | kr 60.1B | +27.5% | +75.5% | |
| Free Cash Flow (FCF) | kr 48.7B | kr 66.7B | kr 83.1B | kr 73.8B | kr 59.0B | −20.1% | +4.9% | |
| True FCF (ex-SBC Owner Cash) | kr 48.7B | kr 66.7B | kr 83.1B | kr 73.8B | kr 59.0B | −20.1% | +4.9% | |
| Dividends Paid | kr 21.5B | kr 25.3B | kr 31.8B | kr 44.1B | kr 51.8B | +17.3% | +24.5% | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what NVO did at the next close after each storySep 17
Novo Nordisk ends two more heart-drug trials as pipeline setbacks mount
+0.12%Yahoo Finance · 7:37 PM ET
Jul 6
Novo Nordisk's oral semaglutide now available in UK pharmacies as Wegovy alternative
—BBC Business · 7:09 AM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.